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OSTEOARTHRITIS 
and 
CARTILAGE 
LETTER TO THE EDITOR 
Sir, 
In the article 'Effect of diacetylrhein on the 
development of experimental osteoarthritis. A 
biochemical investigation', from Dr S. L. Carney 
published in Osteoarthritis and Cartilage (1996; 4: 
251-261) interesting results are described on the 
effects of diacetylrhein on cartilage matrix 
constituents in an experimental model of osteo- 
arthritis in beagle bitches. 
However, in the discussion the author writes 
that: 'In various in vitro test systems, hydroxy- 
anthraquinones have been shown to be tumour- 
promoting agents, in particular rhein has been 
demonstrated to exhibit weak clastogenic activity. 
These properties eem to be related to the presence 
of free hydroxyl groups particularly in the 1,8 
position as in rhein'. 
Our Group would like to submit its comments 
regarding these findings: 
Diacetylrhein belongs to the 1,8 dihydroxy- 
anthraquinone-3-carboxylic acid derivatives. It is 
rapidly metabolized leading to the deacetylated 
active derivative, rhein, which is the major form in 
the blood [1]. 
Its original pharmcological aetivity involves 
inhibition of interleukin-lfl [2, 3] and cartilage- 
degrading enzymes [2, 4] 
In well-known and validated animal models of 
osteoarthritis (osteoarthritis nduced by vitamin A 
[5], post-contusion [6 7] and post-patellectomy [8]
osteoarthritis), diacetylrhein was demonstrated to
prevent he development of osteoarthritis. In these 
models, diacetylrhein was shown to be active in 
reducing the macroscopic and microscopic lesions, 
in preventive and therapeutic ways. 
The efficacy and tolerance of diacetylrhein in 
the treatment of the symptoms of osteoarthritis 
was investigated in 34 clinical trials including 
more than 4800 patients. The therapeutic value 
of diacetylrhein was proven in double-blind, 
randomized, controlled studies versus placebo 
[9-11] or reference products uch as naproxen [12] 
and tenoxicam [9]. 
The efficacy of diacetylrhein (50 mg capsules 
twice daily) in the treatment of both major 
forms of osteoarthritis (coxarthrosis as well as 
gonarthrosis) was significant in improving the 
'clinical symptoms of osteoarthritis (pain reduction 
and algo-functional index). The effects both in vitro 
and on animal models of osteoarthritis uggest 
that diacetylrhein might have not only beneficial 
symptomatic effects but also disease-modifying 
effects. In order to evaluate the chondromodulat- 
ing effect of diacetylrhein, a multicenter, prospec- 
tive, randomized, controlled study versus placebo 
of 3 years duration is currently underway in 507 
patients with osteoarthritis [13]. 
A complete international program of toxicologi- 
cal studies was undertaken in preclinical and 
clinical development of diacetylrhein. Diacetyl- 
rhein was screened in a broad spectrum of routine 
toxicology studies, as required internationally for 
the development of new drugs. The study of the 
mutagenic and carcinogenic potential of diacetyl- 
rhein was widely assessed by different inter- 
national institutes. 
These studies were carried out in compliance 
with the current OECD and EEC guidelines and 
conducted according to the Good Laboratory 
Practices. As a result, the studies demonstrate that 
diacetylrhein is safe; this is especially true 
regarding genotoxicity. 
Diacetylrhein (unpublished ata) and its main 
metabolite rhein [14] were screened in a wide range 
of mutagenicity and genotoxicity assays in vitro as 
well as in vivo (Table I). 
• For genic mutation, experiments were conducted 
on five strains of Salmonella typhimurium 
(Ames test) in UK (Microtest Research Limited, 
TIelsington). Diacetylrhein and rhein did not 
induce point mutations in these assays under 
metabolic and non-metabolic conditions at maxi- 
mum concentrations of up to 5000 pg/plate. 
• The point mutation test on a cell culture was 
studied on V79 cells using HPRT locus mutation 
test at doses ranging from 3-100 #g/ml (Institut 
Pasteur of Lille, France). No  mutagenic effect 
was noted. In the mouse lymphoma cell assay, 
diacetylrhein and rhein gave negative results, 
both in the absence and presence of a metaboliz- 
ing system. 
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Table I 
Summary of the results of genotoxicity/carcinogenicity studies 
Upper concentrations tested Results 
Test system Diacetylrhein Rhein Diacetylrhein Rhein 
Ames test +$9 5000 pg/plate 5000 pg/plate - - 
Mouse lymphoma 
cells 
Chinese hamster 
V79 cells 
Chinese hamster 
ovary cells 
Micronucleus (mice) 
Bone marrow cells (rat) 
Carcinogenicity 
-$9 5000 pg/plate 5000 #g/plate - - 
+$9 220 pg/ml 50 pg/ml - - 
-$9 220 #g/ml 50 #g/ml - - 
+$9 100 pg/ml 
-$9 100 #g/ml 
+$9 220 pg/ml - - 
-$9 220 pg/ml 
1500 mg/kg - - 
2000 mg/kg 
Rat 20 mg/kg 
Mouse 50 mg/kg 
50 #g/ml 
50 #g/mt 
1500 mg/kg 
- negative, non-genotoxic or non-carcinogenic. ~ 
• The clastogenic potential of diacetylrhein and 
rhein was assayed using the chromosome aberra- 
tion test on in vitro and in vivo models. These 
experiments were conducted in France (Institut 
Pasteur of Lille and Hazleton) and in Germany. 
In vitro tests were carried out in Chinese hamster 
ovary cells. Each of the compounds did not 
induce chromosome aberrations under metabolic 
or non-metabolic conditions. Due to their limited 
solubility, the highest concentrations tested were 
50 #g/ml with rhein and 220/~g/ml with diacetyl- 
rhein. In the in vivo micronucleus test, mice 
treated with a single oral dose of 1500 mg/kg of 
diacetylrhein or rhein showed no significant 
differences to control with respect of the 
frequency of micronucleated po lychromat ic  
erythrocytes in the bone marrow. In contrast o 
the statement of Carney, we could not confirm 
that rhein has clastogenic potential. From our 
opinion, the relevant l iterature does not give any 
valid data that rhein could induce chromosomal 
aberrations. 
• In the chromosome aberration assay in Wistar 
rats, diacetylrhein after a single oral treatment 
of 20, 200 and 2000mg/kg, did not induce 
chromosome mutations as determined by 
aberration frequencies in bone marrow cells of 
the rat. 
We would like to stress that all these exper- 
iments (five in vitro and in vivo tests of 
mutagenicity) showed that both diacetylrhein and 
rhein possess neither a mutagenic nor a genotoxic 
potential. 
During this development program, the relation- 
ship between the structure o f  the hydroxy- 
anthraquinones and their mutagenic potential 
were studied. The results of these studies led to 
the conclusion that the presence of  the free 
hydroxymethyl function in position 3 is respon- 
sible for a mutagenic activity; this is not the case 
for diacetylrhein or rhein in wl~ich that position 
is blocked by a carboxyl function. This function 
is not reduced during the metabotization of the 
product, which explains the absence~ of mutagenic 
activity of diacetylrhein, in vivo and $n vitro in the 
presence of metabolic activation. 
Many chemical developments in order to 
improve the quality and purity of diaeetylrhein 
were performed to obtain a product free of these 
impurities. In addition the process of synthesis and 
purification of diacetylrhein leading to a product 
free of hydroxymethylated impurities (mainly 
aloemodine) is patented; in this case, diacetylrhein 
obtained by this procedure is total ly devoid of any 
mutagenic or clastogenic effects. When non- 
purified diacetylrhein or rhein is used, it is clearly 
demonstrated that the mutagenicity is related to 
these impurities. 
Relating to the potential tumour-promoting 
effect of the hydroxyanthraquinones, anytest has 
been validated to produce relevant results. The 
malignant cell transformation assay mentioned in 
l iterature [15] is not validated. Therefore, it is not 
justified, scientifically, to use such data for risk 
assessment. 
In addition to all the mutagenic assays, 
diacetylrhein was studied in both rats and mice 
for its carcinogenic potential. These experiments 
were carried out in UK (Inveresk Research 
International). Animals were treated by oral route 
for 2 consecutive years with different doses of 
diacetylrhein i rats and mice. Each dosing group 
contains 50 animals of both sex. Rhein blood levels 
have been monitored uring the study showing a 
good relationship between administrated oses 
and blood levels. 
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The f indings of these studies did not  demonst ra te  
any carc inogenic  potent ia l  of d iacety l rhe in  and 
conf i rmed the n~gat ive resul ts  of the genotox ic i ty  
test ing.  Therefore,  it can be concluded that  
d iacety l rhe in  is safe for human use. 
We hope that  these informat ion,  which 
emphasize the efforts of our  group to get a safe 
product  for human use, wil l  be helpful  for a bet ter  
unders tand ing  of this subject.  
P. H. BRUN 
International Development Manager, 
Negma Laboratoires, 
Avenue de l'Europe, 
Toussus-le-Noble, 
78771 Magny les Hameaux 
Cedex, 
France 
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